A Phase I, Open Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of GW572016 in Once Daily Versus Twice Daily Dosing Regimens in Patients With Treatment- Naive Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Lapatinib (Primary)
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- Sponsors GlaxoSmithKline
- 14 Aug 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Nov 2006 New trial record.